search
Back to results

TDCS to Improve Post-Stroke Cognitive Impairment (TIPSCI)

Primary Purpose

Stroke, Stroke Sequelae, Cognitive Impairment

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Anodal transcranial Direct Current Stimulation (A-tDCS)
Sham Intervention
Sponsored by
Johns Hopkins University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adults (≥18 years) presenting with neurological symptoms due to acute ischemic stroke (symptom onset within the week prior to admission).
  2. Evidence on brain MRI of acute ischemic stroke (imaging negative strokes and TIAs will be excluded).
  3. Native English speaker (by self-report) prior to stroke.
  4. NIHSS <8 at initial follow-up visit (approximately 30 days post-stroke).
  5. mRS 0-2 at initial follow-up visit.

Exclusion Criteria:

  1. Primary intracerebral hemorrhage- as evidenced by blood on head CT or MRI.
  2. Presence of proximal large vessel occlusion.
  3. Cortical exam findings including aphasia or neglect.
  4. Prior report or history of dementia or undertreated psychiatric illness.
  5. Uncorrected hearing or visual loss.
  6. Inability to attend treatment or follow-up sessions.
  7. Inability to travel to College Park (UMD) for MEG recording sessions.
  8. Presence of any of the following that would lead to significant artifact on MEG: cardiac pacemaker, intracranial clips, metal implants or external clips within 10mm of the head, metal implants in the eyes (unlikely given that all patients will have an MRI and criteria are similar).
  9. Claustrophobia, obesity, and/or any other reason leading to difficulty staying in the MEG machine for up to 1 hour.

Sites / Locations

  • Johns Hopkins Bayview Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

A-tDCS

Sham Intervention

Arm Description

Participants randomized to tDCS will undergo 15- 30 minute sessions over 5 weeks of A-tDCS to the ipsilesional frontoparietal cortex while participating in computerized cognitive therapy (CCT).

Participants randomized to sham will undergo 15- 30 minute sessions over 5 weeks of a sham-intervention, also applied to the ipsilesional frontoparietal cortex, while participating in computerized cognitive therapy (CCT).

Outcomes

Primary Outcome Measures

Change in Cognition as assessed by our Cognitive Battery
Our cognitive battery was designed to efficiently evaluate for psMCI. It combines the Montreal Cognitive Assessment, Grooved Pegboard, Hopkins Verbal Learning Test, Brief Visuospatial Memory Test, Delis-Kaplan Executive Function System, and Symbol Digit Modalities Test. T scores are averaged across tasks and calculated for the following cognitive domains: verbal memory, spatial memory, processing speed, motor speed, executive function, and global cognition.
Change in Functional Connectivity as assessed by MEG
Participants will undergo an MEG evaluating global functional connectivity: 1) during resting state, and 2) during completion of a visual task. Connectivity will also be evaluated within the following specific cognitive networks: frontoparietal (executive) and limbic (memory)

Secondary Outcome Measures

Full Information

First Posted
January 4, 2022
Last Updated
September 8, 2023
Sponsor
Johns Hopkins University
Collaborators
University of Maryland, College Park
search

1. Study Identification

Unique Protocol Identification Number
NCT05195398
Brief Title
TDCS to Improve Post-Stroke Cognitive Impairment
Acronym
TIPSCI
Official Title
TDCS to Improve Post-Stroke Cognitive Impairment
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2022 (Actual)
Primary Completion Date
August 31, 2026 (Anticipated)
Study Completion Date
August 31, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johns Hopkins University
Collaborators
University of Maryland, College Park

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators will conduct a randomized, double-blinded, sham-controlled trial of approximately 60 patients with minor stroke and post-stroke mild cognitive impairment (psMCI). Participants will be individually randomized on enrollment using a random number generator to treatment with anodal tDCS + computerized cognitive treatment (CCT) versus sham + CCT (approximately 30 patients in each arm). Clinical evaluation including assessment of cognition will be performed pre- and post-intervention by individuals on the study team blinded to the participant's intervention. Participants will also undergo functional neuroimaging with magnetoencephalography (MEG) pre- and post-intervention (1, 3, and 6 months post-stroke to evaluate for initial and longer-term effects of treatment on cerebral activation patterns and functional connectivity). Neuroimaging and clinical outcomes will be assessed to determine the effect of tDCS versus sham + CCT on psMCI.
Detailed Description
Vascular cognitive impairment, ranging from vascular mild cognitive impairment to vascular dementia, is a leading cause of progressive cognitive dysfunction second only to Alzheimer Disease. While the accumulation of ischemic infarcts or a large cortical stroke can result in permanent cognitive dysfunction, a single small stroke can also result in disabling impairment. The investigators have shown that small lesions, regardless of the location, result in acute cognitive decline. Similar to those with progressive vascular cognitive impairment, post-stroke MCI (psMCI) patients display slowed reaction times and dysfunction across multiple cognitive domains. Many significantly recover over the first 6 months. However, the heterogenous recovery and uncertainty regarding prognosis can lead to major life changes, such as early retirement or selling of homes, that substantially impact quality of life. Magnetoencephalography (MEG) recordings in those with psMCI show temporal dispersion consistent with generalized disruption of cognitive networks during resting state, irrespective of lesion location. Evaluation of frequency spectra show bilaterally decreased beta power in the frontoparietal lobes correlating with impaired reaction times. Functional connectivity analyses at 6 months demonstrate increased inter-hemispheric connections that may explain or reflect a patient's improvement. It is currently unknown whether specific cognitive networks are involved, though based on the pattern of clinical deficits it would be reasonable to hypothesize that the frontoparietal network, responsible for executive function and higher level cognitive tasks, is disrupted to a greater extent than the limbic, responsible for emotion and memory. Neural modulation with transcranial direct current stimulation (tDCS) increases the likelihood of neural firing, strengthening connectivity by promoting long-term potentiation and facilitating task performance. As anodal tDCS only induces the firing of neurons near threshold, it follows that it is most effective and longest acting when paired with a task that engages focal activation. This is best seen in patients with aphasia undergoing speech-language therapy. In this study, the investigators will determine the utility of A-tDCS in conjunction with computerized cognitive therapy (CCT) to treat psMCI. The investigators will recruit approximately 60 patients with subacute minor stroke and randomize the patients to A-tDCS administered over the ipsilesional frontoparietal cortex versus sham plus 15 sessions of cognitive therapy using a widely used online platform focused most on executive functioning and processing speed based on the investigators' preliminary work targeting deficits most specific to those with psMCI. The investigators hypothesize that tDCS will augment both generalized connectivity as well as the connectivity of specific networks targeted during training (most notably the frontoparietal) and that patients will show increased clinical improvement acutely after therapy that will last for months after treatment. Along with clinical evaluation, the investigators will use MEG to evaluate cerebral activation patterns and connectivity pre- (1 month post-infarct) and post- (3 and 6 months post-infarct) intervention. The investigators will collect longitudinal MEG and clinical data through a multicenter collaboration of experts in the fields of stroke, dementia, and functional neuroimaging.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Stroke Sequelae, Cognitive Impairment

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients will be randomized to 15- 30 minute sessions of A-tDCS + CCT versus sham-intervention + CCT over a 5 week period
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
A-tDCS
Arm Type
Experimental
Arm Description
Participants randomized to tDCS will undergo 15- 30 minute sessions over 5 weeks of A-tDCS to the ipsilesional frontoparietal cortex while participating in computerized cognitive therapy (CCT).
Arm Title
Sham Intervention
Arm Type
Active Comparator
Arm Description
Participants randomized to sham will undergo 15- 30 minute sessions over 5 weeks of a sham-intervention, also applied to the ipsilesional frontoparietal cortex, while participating in computerized cognitive therapy (CCT).
Intervention Type
Device
Intervention Name(s)
Anodal transcranial Direct Current Stimulation (A-tDCS)
Other Intervention Name(s)
Computerized Cognitive Therapy (CCT)
Intervention Description
Participants randomized to tDCS will undergo 5 weeks of A-tDCS + CCT.
Intervention Type
Device
Intervention Name(s)
Sham Intervention
Other Intervention Name(s)
Computerized Cognitive Therapy (CCT)
Intervention Description
Participants randomized to sham-intervention will undergo 5 weeks of sham + CCT.
Primary Outcome Measure Information:
Title
Change in Cognition as assessed by our Cognitive Battery
Description
Our cognitive battery was designed to efficiently evaluate for psMCI. It combines the Montreal Cognitive Assessment, Grooved Pegboard, Hopkins Verbal Learning Test, Brief Visuospatial Memory Test, Delis-Kaplan Executive Function System, and Symbol Digit Modalities Test. T scores are averaged across tasks and calculated for the following cognitive domains: verbal memory, spatial memory, processing speed, motor speed, executive function, and global cognition.
Time Frame
Administered at 1, 3, and 6 month post-stroke visits
Title
Change in Functional Connectivity as assessed by MEG
Description
Participants will undergo an MEG evaluating global functional connectivity: 1) during resting state, and 2) during completion of a visual task. Connectivity will also be evaluated within the following specific cognitive networks: frontoparietal (executive) and limbic (memory)
Time Frame
Administered at 1, 3, and 6 month post-stroke visits

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults (≥18 years) presenting with neurological symptoms due to acute ischemic stroke (symptom onset within the week prior to admission). Evidence on brain MRI of acute ischemic stroke (imaging negative strokes and TIAs will be excluded). Native English speaker (by self-report) prior to stroke. NIHSS <8 at initial follow-up visit (approximately 30 days post-stroke). mRS 0-2 at initial follow-up visit. Exclusion Criteria: Primary intracerebral hemorrhage- as evidenced by blood on head CT or MRI. Presence of proximal large vessel occlusion. Cortical exam findings including aphasia or neglect. Prior report or history of dementia or undertreated psychiatric illness. Uncorrected hearing or visual loss. Inability to attend treatment or follow-up sessions. Inability to travel to College Park (UMD) for MEG recording sessions. Presence of any of the following that would lead to significant artifact on MEG: cardiac pacemaker, intracranial clips, metal implants or external clips within 10mm of the head, metal implants in the eyes (unlikely given that all patients will have an MRI and criteria are similar). Claustrophobia, obesity, and/or any other reason leading to difficulty staying in the MEG machine for up to 1 hour.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elisabeth B Marsh, MD
Phone
410-550-8703
Email
ebmarsh@jhmi.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elisabeth B Marsh, MD
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johns Hopkins Bayview Medical Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21224
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eliabeth B Marsh, MD
Phone
410-550-8703
Email
ebmarsh@jhmi.edu
First Name & Middle Initial & Last Name & Degree
Rafael H Llinas, MD
Phone
4105501042
Email
rllinas@jhmi.edu

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Results in aggregate will be posted; however, de-identified individual participant data will be made available to other investigators and potential collaborators upon reasonable request of the PI.
IPD Sharing Time Frame
One year following completion of data collection and publication of results.
Citations:
PubMed Identifier
33318200
Citation
Marsh EB, Brodbeck C, Llinas RH, Mallick D, Kulasingham JP, Simon JZ, Llinas RR. Poststroke acute dysexecutive syndrome, a disorder resulting from minor stroke due to disruption of network dynamics. Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):33578-33585. doi: 10.1073/pnas.2013231117. Epub 2020 Dec 14.
Results Reference
background
PubMed Identifier
29306185
Citation
Marsh EB, Lawrence E, Hillis AE, Chen K, Gottesman RF, Llinas RH. Pre-stroke employment results in better patient-reported outcomes after minor stroke: Short title: Functional outcomes after minor stroke. Clin Neurol Neurosurg. 2018 Feb;165:38-42. doi: 10.1016/j.clineuro.2017.12.020. Epub 2017 Dec 27.
Results Reference
background
PubMed Identifier
33424761
Citation
Sharma R, Mallick D, Llinas RH, Marsh EB. Early Post-stroke Cognition: In-hospital Predictors and the Association With Functional Outcome. Front Neurol. 2020 Dec 23;11:613607. doi: 10.3389/fneur.2020.613607. eCollection 2020.
Results Reference
background
Links:
URL
http://www.marshlab.org
Description
Marsh Lab website

Learn more about this trial

TDCS to Improve Post-Stroke Cognitive Impairment

We'll reach out to this number within 24 hrs